What happened
Smith+Nephew plc (NYSE: SNN) cut its full-year trading profit growth forecast to around 4% from around 8% in a third-quarter update on Nov. 4. The company tied the cut to a lower revenue outlook, citing US hips and knees in the fourth quarter and market conditions.
Underlying revenue growth is now expected at around 3%, down from around 4%. Trading profit is seen at around $1.25 billion, down from around $1.3 billion. Free cash flow is expected at around $750 million, down from around $800 million. Trading cash conversion stays at around 95%, in line with original guidance. Adjusted return on invested capital is expected at around 9%, down from more than 10%.
The quarter held up better than the outlook. Q3 revenue was $1.55 billion, up from $1.50 billion a year earlier, a 3.4% rise on both an underlying and reported basis. Sports Medicine ENT grew 7.9% underlying to $507 million. US Knee Implants revenue fell 7.3% and US Hip Implants revenue fell 1.0%.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Q3 revenue | $1.55 billion | from $1.50 billion, +3.4% | SEC 6-K |
| Full-year underlying revenue growth guidance (previously around 4%) | around 3% | SEC 6-K | |
| Full-year trading profit growth guidance (previously around 8%) | around 4% | SEC 6-K | |
| Full-year free cash flow guidance (previously around $800 million) | around $750 million | SEC 6-K | |
| Adjusted ROIC guidance (previously more than 10%) | around 9% | SEC 6-K | |
| Share buyback completed by end of Q3 (of $500 million) | $250 million | SEC 6-K |
Read more: Smith+Nephew (SNN) company research
Why it matters
OptimistFi has argued that mid-single-digit growth and better margins drive the company's cash returns. The new guidance puts full-year revenue growth below that pace, so the case is mixed. Q3 revenue added $50 million to the year-earlier total.
Some supports remain. Guidance still has trading profit growing faster than revenue, and cash conversion is unchanged. CEO Deepak Nath said the company remains confident in profit growth ahead of revenue growth.
The caveat is US Orthopaedics. Nath said slower growth there is expected to continue through the fourth quarter. The Board has also been weighing strategic options for Orthopaedics. Smith+Nephew said it approached Johnson & Johnson earlier in the year, that talks took place and that they have now ended.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
Smith+Nephew will report fourth-quarter and full-year 2026 results on March 1, 2027. Delivery at the lowered guidance would steady the case. Another cut tied to US hips and knees would weaken it.
The $500 million buyback, announced May 6, has $250 million completed. It is due to finish within twelve months of that date.
More from OptimistFi
From OptimistFi Perps
- Top perps movers today: stocks, commodities, FX and indices
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
Sources
- Smith+Nephew Third Quarter 2026 Trading Update (Form 6-K) — Form 6-K dated Nov. 4, 2026, covering the quarter ended Sept. 26, 2026.
Explore OptimistFi research on Smith+Nephew plc: https://optimistfi.com/stocks/SNN
Browse Smith+Nephew plc company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the Smith+Nephew plc company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
